Drug Profile
Research programme: HIV entry inhibitors - Pharmacopeia Drug Discovery/Progenics
Alternative Names: HIV attachment inhibitors - Pharmacopeia Drug Discovery/Progenics; HIV entry inhibitors research programme - Pharmacopeia Drug Discovery/Progenics; HIV fusion inhibitors - Pharmacopeia Drug Discovery/ProgenicsLatest Information Update: 19 Jun 2020
Price :
$50
*
At a glance
- Originator Pharmacopeia Drug Discovery; Progenics Pharmaceuticals
- Class Small molecules
- Mechanism of Action CD4 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 21 Aug 2007 Discontinued - Preclinical for HIV infections treatment in USA (PO)
- 26 Aug 2005 No development reported - Preclinical for HIV infections treatment in USA (PO)